What is Rallybio?
Rallybio operates at the intersection of hematology, immuno-inflammation, and metabolism, focusing on the identification and acceleration of novel drug candidates. The company's market position is defined by its specialized approach to rare disease research, where it leverages deep scientific expertise to navigate the complexities of clinical development. By targeting high-unmet-need patient populations, Rallybio differentiates itself through a focused, high-impact R&D strategy that aims to deliver therapeutic solutions where traditional pharmaceutical approaches have historically struggled to gain traction.
How much funding has Rallybio raised?
Rallybio has raised a total of $355.8M across 4 funding rounds:
Series A
$37M
Share Placement
$93.2M
Series B
$145M
Share Placement
$80.6M
Series A (2018): $37M, investors not publicly disclosed
Share Placement (2020): $93.2M, investors not publicly disclosed
Series B (2020): $145M supported by The Rise Fund, VIKING GLOBAL INVESTORS L.P., Solasta Ventures, F-Prime Capital, Fairview Capital Partners Inc, Tekla Life Sciences Investors, MITSUI & CO LTD, and PIVOTAL BIOVENTURE PARTNERS LLC
Share Placement (2021): $80.6M, investors not publicly disclosed
Key Investors in Rallybio
The Rise Fund
The Rise Fund is an impact investing platform that focuses on growth-stage, mission-driven companies aligned with the United Nations' Sustainable Development Goals, specializing in healthcare and social outcomes.
F-Prime Capital
F-Prime Capital is a Massachusetts-based investment firm comprised of scientists, doctors, and engineers dedicated to fostering innovation within the healthcare and technology sectors.
MITSUI & CO LTD
Mitsui & Co. is a global trading and investment conglomerate that leverages its extensive international network to support industry growth and enhance quality of life through healthcare solutions.
What's next for Rallybio?
With the infusion of capital from its recent strategic financing, Rallybio is well-positioned to accelerate its clinical trial programs and expand its therapeutic reach. The company's forward-looking strategy involves deepening its research capabilities and potentially broadening its portfolio through internal innovation and strategic partnerships. As the firm moves further into its clinical lifecycle, the focus will likely shift toward regulatory milestones and the commercialization of its lead candidates, ensuring that its mission-driven approach translates into tangible patient outcomes and long-term shareholder value.
See full Rallybio company page
